Patents by Inventor Kieren A. Marr
Kieren A. Marr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11592445Abstract: The present invention describes methods of using Olfr90 demonstrated to bind to fungal metabolites, including a metabolite known to be detected in patients with mold (e.g. Aspergillus) infections.Type: GrantFiled: September 24, 2018Date of Patent: February 28, 2023Assignee: The Johns Hopkins UniversityInventors: Jennifer Pluznick, Kieren A. Marr, Victoria H. Kuhns
-
Publication number: 20210364515Abstract: Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.Type: ApplicationFiled: July 29, 2021Publication date: November 25, 2021Inventor: Kieren Marr
-
Patent number: 11079380Abstract: Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.Type: GrantFiled: January 23, 2020Date of Patent: August 3, 2021Assignee: The Johns Hopkins UniversityInventor: Kieren Marr
-
Publication number: 20200225224Abstract: Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.Type: ApplicationFiled: January 23, 2020Publication date: July 16, 2020Inventor: Kieren Marr
-
Publication number: 20200209238Abstract: Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of polysaccharide antigenic components. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF—containing antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing Intelectin-1 binding to galF—containing antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to Streptococcus pneumoniae, Klebsiella pneumonia, Escherichia coli, Mycobacteria species, Malassezia species, Aspergillus species, Fusarium species, Alternaria species, Coccidioides species, Cryptococcus species, Mucormycetes, Histoplasma species, Neosartorya species, Fusarium species, Paracoccidioides species, or combinations thereof.Type: ApplicationFiled: May 9, 2018Publication date: July 2, 2020Inventors: Kieren Marr, Kausik Datta
-
Patent number: 10585098Abstract: Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.Type: GrantFiled: January 29, 2018Date of Patent: March 10, 2020Assignee: The Johns Hopkins UniversityInventor: Kieren A. Marr
-
Patent number: 10288611Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.Type: GrantFiled: November 23, 2010Date of Patent: May 14, 2019Assignees: The Johns Hopkins University, Albert Einstein College of Medicine, Inc.Inventors: Kieren A. Marr, Janet F. Staab, Marta Feldmesser
-
Publication number: 20190064161Abstract: The present invention describes methods of using Olfr90 demonstrated to bind to fungal metabolites, including a metabolite known to be detected in patients with mold (e.g. Aspergillus) infections.Type: ApplicationFiled: September 24, 2018Publication date: February 28, 2019Inventors: Jennifer Pluznick, Kieren A. Marr, Victoria H. Kuhns
-
Patent number: 10107822Abstract: Methods, kits, and diagnostic devices are disclosed for diagnosing an invasive fungal infection in a subject by measuring a T-cell interferon gamma (IFN-?) response after exposure to a fungal antigen.Type: GrantFiled: December 16, 2014Date of Patent: October 23, 2018Assignee: The Johns Hopkins UniversityInventor: Kieren Marr
-
Publication number: 20180156797Abstract: Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.Type: ApplicationFiled: January 29, 2018Publication date: June 7, 2018Inventor: Kieren A. Marr
-
Patent number: 9915657Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., through a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigatus for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.Type: GrantFiled: November 18, 2014Date of Patent: March 13, 2018Assignees: YESHIVA UNIVERSTIY, THE JOHNS HOPKINS UNIVERSITYInventors: Kieren A. Marr, Marta Feldmesser, Janet F. Staab
-
Publication number: 20160313346Abstract: Methods, kits, and diagnostic devices are disclosed for diagnosing an invasive fungal infection in a subject by measuring a T-cell interferon gamma (IFN-?) response after exposure to a fungal antigen.Type: ApplicationFiled: December 16, 2014Publication date: October 27, 2016Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: KIEREN MARR
-
Publication number: 20150192581Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carriers with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., through a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.Type: ApplicationFiled: November 18, 2014Publication date: July 9, 2015Applicants: YESHIVA UNIVERSITY, THE JOHNS HOPKINS UNIVERSITYInventors: Kieren A. Marr, Marta Feldmesser, Janet F. Staab
-
Publication number: 20130017561Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.Type: ApplicationFiled: November 23, 2010Publication date: January 17, 2013Applicants: YESHIVA UNIVERSITY, THE JOHNS HOPKINS UNIVERSITYInventors: Kieren A. Marr, Janet F. Staab, Marta Feldmesser
-
Publication number: 20100326218Abstract: The present invention provides a method of identifying a subject having a haplotype in a toll-like receptor 4 gene of the subject that is associated with an increased risk of invasive mold infection in a recipient of a transplant from the subject, comprising genotyping the subject for the presence of particular single nucleotide polymorphisms or haplotypes in the toll-like receptor 4 gene of the subject, wherein the detection of said single nucleotide polymorphism(s) and/or haplotype(s) identifies the subject as having a single nucleotide polymorphism and/or haplotype associated with an increased risk of invasive mold infection in a recipient of a transplant from the subject.Type: ApplicationFiled: September 26, 2008Publication date: December 30, 2010Inventors: Michael Boeckh, Jason W. Chien, Kieren Marr, Pierre-Yves Bochud